Pharma IQ Members

Anantharaman
Kavassery Viswanathan

Anantharaman Kavassery Viswanathan, analyst at Datamonitor Healthcare, said: “In this latest round of cuts the market expansion rule will impact 11 active ingredients (APIs) and 22 products which mostly include big-selling DPP-4 inhibitor antidiabetics and biologic therapies used mainly in rheumatoid arthritis. Overall, the average cut of 5.64%...Full Article »